Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01307501 · ClinicalTrials.gov registry record · NA

Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

A NA study, sponsored by Boston Scientific Corporation.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT01307501 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01307501, a NA study, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.

Interventions

  • DEVICE Cryoablation

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2012-01-04
Est. Completion 2018-08-30
Phase NA

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT01307501

The ClinicalTrials.gov registry entry for NCT01307501 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Cryoablation is the first listed.

NCT01307501 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01307501 about?

NCT01307501 is a clinical study titled "Safety and Efficacy of Cryoablation for Metastatic Lung Tumors". ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.

What is the current status of trial NCT01307501?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2012-01-04. Estimated completion is 2018-08-30.

What interventions are being tested in trial NCT01307501?

The interventions under investigation include: Cryoablation (DEVICE).

Who is sponsoring clinical trial NCT01307501?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.